• Publications
  • Influence
Inhaler competence in asthma: common errors, barriers to use and recommended solutions.
TLDR
This review takes forward the challenge of inhaler competence by highlighting the issues and suggesting potential solutions to these problems, as most issues faced by patients have not changed for half a century and this situation should not be allowed to continue any longer. Expand
Inhaling to mitigate exhaled bioaerosols.
TLDR
It is hypothesized that, by altering lung airway surface properties through an inhaled nontoxic aerosol, this work might substantially diminish the number of exhaled bioaerosol droplets and thereby provide a simple means to potentially mitigate the spread of airborne infectious disease independently of the identity of the airborne pathogen or the nature of any specific therapy. Expand
Clinical perspectives on pulmonary systemic and macromolecular delivery.
TLDR
The physical and in part some of the physiological requirements that need to be considered for the optimization of pulmonary drug delivery to target certain lung regions are described. Expand
Deposition, retention, and translocation of ultrafine particles from the central airways and lung periphery.
TLDR
Within the limits of detection of the experimental system, most inhaled ultrafine carbon particles are retained in the lung periphery and in the conducting airways without substantial systemic translocation or accumulation in the liver at 48 hours. Expand
Mass output and particle size distribution of glucocorticosteroids emitted from different inhalation devices depending on various inspiratory parameters.
TLDR
It is found that, beside the peak inspiratory flow (PIF), other factors such as flow acceleration and inhalation volume also have significant effects on aerosol generation with respect to mass output and particle size distribution. Expand
Inhaled insulin--does it become reality?
TLDR
The first pulmonary delivered version of insulin (Exubera) from Pfizer/Nektar early 2006 was approved but in October 2007, Pfizer announced it would be taking Exubera off the market, citing that the drug had failed to gain market acceptance. Expand
Short-term and long-term clearance of particles from the upper human respiratory tract as function of particle size
Abstract Human lung clearance was measured following aerosol inhalations with small boluses injected to very shallow lung depths. For 1 and 3 μm particles only about 50% of the deposited aerosolsExpand
An approach to deposition and clearance measurements in human airways.
TLDR
It could be shown that the mucociliary clearance from the airways was particle size dependent and the clearance efficiency from theAirways increased with increasing particle size. Expand
The inhalation manager: a new computer-based device to assess inhalation technique and drug delivery to the patient.
TLDR
The development of a new system, the Inhalation Manager, which, for the first time, offers the possibility to assess the entire inhalation maneuver of patients using original devices under everyday conditions, and could become an essential tool in asthma management. Expand
...
1
2
3
4
5
...